| Title: |
High karyotypic complexity is an independent prognostic factor in patients with CLL treated with venetoclax combinations |
| Authors: |
Fürstenau, Moritz; Thus, Yvonne J; Robrecht, Sandra; Mellink, Clemens HM; van der Kevie-Kersemaekers, Anne-Marie; Dubois, Julie; von Tresckow, Julia; Patz, Michaela; Gregor, Michael; Thornton, Patrick; Staber, Philipp B.; Tadmor, Tamar; Levin, Mark-David; da Cunha-Bang, Caspar; Schneider, Christof; Poulsen, Christian Bjoern; Illmer, Thomas; Schöttker, Björn; Janssens, Ann; Christiansen, Ilse; Nösslinger, Thomas; Baumann, Michael; Hebart, Holger; Gaska, Tobias; Regelink, Josien C; Dompeling, Ellen C; Lindström, Vesa; Juliusson, Gunnar; Widmer, Anouk; Goede, Jeroen; Goldschmidt, Neta; Simon, Florian; De Silva, Nisha; Fink, Anna-Maria; Fischer, Kirsten; Wendtner, Clemens-Martin; Ritgen, Matthias; Brüggemann, Monika; Tausch, Eugen; Spaargaren, Marcel; Eldering, Eric; Stilgenbauer, Stephan; Niemann, Carsten U; Hallek, Michael; Eichhorst, Barbara; Kreuzer, Karl-Anton; Kater, Arnon P |
| Contributors: |
HUS Comprehensive Cancer Center; Department of Oncology; Hematologian yksikkö |
| Publisher Information: |
Elsevier B.V. |
| Publication Year: |
2024 |
| Collection: |
Helsingfors Universitet: HELDA – Helsingin yliopiston digitaalinen arkisto |
| Subject Terms: |
Cancers; Chronic lymphocytic-leukemia; Chromosomal translocations; Ibrutinib; Survival; Acalabrutinib; Chlorambucil; Aberrations; Multicenter |
| Description: |
Complex karyotypes have been associated with inferior outcomes in chronic lymphocytic leukemia (CLL) treated with chemoimmunotherapy (CIT) while their prognostic impact in the context of venetoclax-based treatments is still debated. In this prospective analysis on karyotype complexity in CLL, we evaluated the impact of complex (≥3 chromosomal aberrations [CA], CKT) and highly complex karyotypes (≥5 CA, hCKT) as well as specific aberrations in previously untreated patients without TP53 aberrations undergoing either CIT or time-limited venetoclax-based therapies in the phase 3 GAIA/CLL13 trial. Karyotype analyses were available for 895 of 926 (96.7%) patients of whom 153 (17%) had a CKT and 43 (5%) hCKT. In the CIT arm, CKT was associated with shorter PFS (HR 2.58, 95%CI 1.54-4.32, p ; Peer reviewed |
| Document Type: |
article in journal/newspaper |
| File Description: |
application/pdf |
| Language: |
English |
| Relation: |
The authors thank all patients and their families, physicians, and study teams at the sites for their participation and great contributions to this study. They especially thank Emily Holmes, Kerstin Loeschke, Alana Hoenig, Johanna Wesselmann, Lisa Engel, Verena Bonigut, Marina Stockem, Dana Engelhardt, Katharina Loehers, and Anne Westermann, who worked as project managers; Florian Drey, Ronald D'Brot, Dilara Celik, Joern Harrandt, Viktoria Monar, Uyen Nguyen, Anna Schlo beta nagel, Johannes Poeppinghaus, Michael Verhuelsdonk, Annette Niederhausen, Irene Prei beta ler-Stodden, Olga Korf, Jan-Erik Mittler, Henrik Gerwin, Alwina Flock, Sally Huggins, Anna Wetzel, and Giovanna Gelmi, who worked as data managers; and Sabine Frohs, Tanja Annolleck, Berit Falkowski and Christina Rhein, who worked as safety managers in the GAIA trial. The trial was sponsored by the German CLL Study Group with financial support and study drug provision from Roche, AbbVie, and Janssen. This analysis was partly supported by a Dutch Cancer Foundation grant (Coherent: 13650/2021-Infra).; RIS: urn:3CA692DB00D935E6B4049C472DE04103; https://hdl.handle.net/10138/575306; 85161324651; 001058567800001 |
| Availability: |
https://hdl.handle.net/10138/575306 |
| Rights: |
info:eu-repo/semantics/openAccess ; openAccess |
| Accession Number: |
edsbas.54FE0B50 |
| Database: |
BASE |